login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Janssen withdraws supplemental new drug application for rivaroxaban


Tuesday, 10 Jul 2012 14:31

Janssen R&D has announced it is withdrawing the supplemental new drug application (sNDA) to the FDA for the use of rivaroxaban (Xarelto, Bayer/Janssen) to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS).


The company is withdrawing this sNDA because it is contingent on a separate sNDA, for rivaroxaban to reduce the risk of secondary cardiovascular events in patients with ACS, which Janssen R&D received a complete response letter from the FDA on 21 June 2012. Data from the ATLAS ACS 2 TIMI 51 trial support both sNDAs.

“We remain confident in the overall study results from the ATLAS ACS 2 TIMI 51 trial, including the observed reduction in stent thrombosis that formed the basis for this separate sNDA,” said Burton. “Our top priority is to work with FDA on our original sNDA for ACS and submit our reply to the complete response letter as soon as possible. We plan to resubmit the sNDA for stent thrombosis at the same time.”




Add New Comment

Most popular


Three studies show benefits of Perceval sutureless valve
Wednesday, 22 Oct 2014
Three studies presented at the 2014 EACTS annual meeting showed positive data for Sorin’s sutureless Perceval aortic valve. Three studies show benefits of Perceval sutureless valve

Medtronic launches Resolute Onyx drug-eluting stent following CE mark approval
Tuesday, 04 Nov 2014
Medtronic has undertaken the international launch of its Resolute Onyx drug-eluting stent following the receipt of CE mark approval. The first live patient implant of the Resolute Onyx occurred ... Medtronic launches Resolute Onyx drug-eluting stent following CE mark approval

New data from EVOLVE clinical programme demonstrate SYNERGY success
Friday, 21 Nov 2014
In the first successful US pivotal trial of a bioabsorbable polymer stent, the Boston Scientific everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its primary ... New data from EVOLVE clinical programme demonstrate SYNERGY success

Features


Performing TAVI in a hybrid operating room
Wednesday, 10 Dec 2014
Daniel O’ Hair believes hybrid ORs may provide distinct advantages for complex TAVI cases. He speaks to Cardiovascular News about his experience of performing TAVI in a hybrid OR. Performing TAVI in a hybrid operating room

First transcatheter tricuspid valve replacement performed in the USA
Friday, 28 Nov 2014
A team at Henry Ford Hospital, Detroit, USA, has successfully performed the first transcatheter tricuspid valve replacement surgery in the USA. First transcatheter tricuspid valve replacement performed in the USA

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions